FDA Peptide Compounding Review 2026: What the 503A Decision Means

On July 23 and 24, 2026, an FDA advisory committee reviewed whether several widely discussed peptides should be added to the list of substances eligible for compounding under Section 503A. The committee voted to recommend six of them and voted against one. Those votes are recommendations only, not final decisions, and no peptide status has changed as a result. This article explains what the review was, what the vote does and does not mean, and what could happen next.

What Happened in July 2026?

The FDA's Pharmacy Compounding Advisory Committee met on July 23 and 24, 2026, to consider bulk drug substances for possible inclusion on the 503A Bulks List. Based on reporting from the meeting, the committee voted to recommend BPC-157, KPV, TB-500, and MOTS-C on July 23, and Epitalon and Semax on July 24. It voted against recommending emideltide. The votes were close, and coverage noted the committee's recommendations ran counter to concerns raised by the FDA's own staff.

An advisory committee vote is a step in a review process, not a final decision. The committee offers a recommendation, and the FDA then decides separately, through rulemaking, whether to add a substance to the 503A Bulks List. The FDA is not bound by the committee and has gone against advisory recommendations before. As of the date of this article, none of these peptides has been added to the list, and all remain in Category 2.

What the 503A Bulks List Is

Section 503A of the Federal Food, Drug, and Cosmetic Act sets the rules for pharmacies that compound medications for individual patients. A compounding pharmacy can generally use a bulk drug substance only if that substance is the subject of an FDA-approved application, has a USP monograph, or appears on the FDA's 503A Bulks List. The list is therefore the pathway by which a non-approved substance can become eligible for outpatient compounding.

The framework sorts nominated substances into two working groups during review:

• Category 1: Substances that may be used in compounding while the FDA completes its evaluation, because they do not raise the significant safety concerns that would pause their use.
• Category 2: Substances the FDA has identified as raising sufficient concern that they should not be compounded while under review.

It is worth stressing that inclusion on the 503A Bulks List is not the same as FDA approval. Approval requires clinical trials and a formal review of safety and effectiveness for a specific use. Eligibility for compounding is a narrower determination about whether a substance may be prepared by a pharmacy for an individual patient with a prescription.

Which Peptides Are Under Review

The peptides the committee recommended remain in Category 2, which means they are not eligible for 503A compounding at this time. A recommendation is not the same as inclusion on the list, and nothing changes for these substances unless and until the FDA acts. Each has been the subject of preclinical or early research interest:

• BPC-157 has been studied for its proposed role in tissue and gut repair processes in preclinical models.
• KPV is a short tripeptide studied for its proposed influence on inflammatory signaling.
• TB-500 is a synthetic fragment studied in the context of tissue repair research.
• MOTS-C is a mitochondrial-derived peptide studied for its proposed role in metabolic regulation.

Because these remain Category 2 substances, they are not currently available through compounding, and this article does not describe how they are used, dosed, or administered. Those questions are determined on a case-by-case basis under medical supervision, and only for substances that are eligible and appropriate.

What "Under Review" Does and Does Not Mean

It is easy to read regulatory headlines as a green light. Here is the more careful reading:

• It does not mean these peptides are legal to compound today. Their status has not changed because a meeting is taking place.
• It does not mean FDA approval. Even a substance added to the 503A Bulks List is not an FDA-approved drug.
• It does not guarantee an outcome. The committee can recommend for or against inclusion, and the FDA makes the final call on its own timeline.
• It does signal that the pathway is active. A formal review is how a Category 2 substance could, in the future, become eligible for compounding.

What a Decision Could Mean for Access

If the FDA were to add a peptide to the 503A Bulks List in the future, that substance could become eligible for compounding by a licensed pharmacy when prescribed for an individual patient. Access would still depend on a medical evaluation, a valid prescription, and a state-licensed compounding pharmacy. Eligibility for compounding and appropriateness for a given person are separate questions, and the second is always determined under medical supervision.

For a fuller explanation of how the two categories work, see "FDA Category 1 vs. Category 2 - What's the Difference?"

Frequently Asked Questions

Are peptides becoming legal in 2026?

An FDA advisory committee has recommended that six peptides be added to the list of substances eligible for compounding, but a recommendation is not a change in law. The FDA still has to decide through rulemaking, and it is not required to follow the committee. No change in status has been finalized as of the date of this article.

Does this mean I can get BPC-157 or KPV now?

No. Despite the committee's recommendation, these remain Category 2 substances and are not currently eligible for compounding. Whether that changes depends on the FDA's final decision, which has not been issued.

Where can I read the FDA's own materials?

The FDA publishes its advisory committee agendas, briefing documents, and the current 503A Bulks List on its website. Links to the primary sources used for this article appear below.

The Bottom Line

The July 2026 advisory committee vote is a genuine step in the process that decides whether peptides like BPC-157, KPV, TB-500, and MOTS-C can be compounded under 503A, but it is only a recommendation. It is not approval, not a change in legal status, and not a signal to seek these peptides from unregulated sellers. The responsible way to follow it is through the FDA's own published materials and licensed medical channels.

Updates

This is a developing story. We add dated entries here as the review progresses, so this page stays the single place to follow it.

• July 25, 2026: Reporting on the meeting confirmed the committee voted to recommend six peptides for the 503A Bulks List - BPC-157, KPV, TB-500, MOTS-C (July 23) and Epitalon and Semax (July 24) - and voted against emideltide. The votes were narrow, and coverage noted the committee's recommendations went against concerns raised by FDA staff. The recommendations are advisory; the FDA has not issued a final rule, and the peptides remain Category 2 for now. See our news summary: FDA panel votes to recommend six peptides.
• July 23, 2026: The FDA Pharmacy Compounding Advisory Committee opened its two-day meeting. BPC-157, KPV, TB-500, and MOTS-C were on the July 23 agenda for discussion of possible inclusion on the 503A Bulks List. No committee recommendation had been published as of this date.